Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
2018
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
2017
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study
2007
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
2002
The DNA-damage response in human biology and disease
2009 StandoutNature
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
S-1 in the treatment of pancreatic cancer
2014
Pancreatic cancer
2004 Standout
Matrix metalloproteinases and the regulation of tissue remodelling
2007 Standout
Inflammation and cancer
2002 StandoutNature
Targeting hypoxia in cancer therapy
2011 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
2014
Rectal Cancer: Primary Staging and Assessment After Chemoradiotherapy
2011
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
2015
Pancreatic cancer
2020 Standout
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
2010
Replicative DNA polymerase mutations in cancer
2014
Cancer Metastasis: Building a Framework
2006 Standout
Lung Cancer
2008 Standout
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
2017
Low-Density Lipoprotein Receptor-Related Protein-1 Mediates Endocytic Clearance of Tissue Inhibitor of Metalloproteinases-1 and Promotes Its Cytokine-Like Activities
2014 StandoutNobel
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
2008
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Pancreatic cancer
2016 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis
2012
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Colorectal cancer
2013 Standout
Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin
2003
Osteoarthritis
2015 Standout
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Colorectal cancer
2019 Standout
Cancer genes and the pathways they control
2004 Standout
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold – A Potential Therapeutic Intervention for Skin Diseases
2016 StandoutNobel
Immunotherapy in colorectal cancer: rationale, challenges and potential
2019
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results
2001
Remodelling the extracellular matrix in development and disease
2014 Standout
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
2012
TIMPs as multifacial proteins
2004
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
Current understanding of the human microbiome
2018 Standout
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
2013
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Bioreductively-activated prodrugs for targeting hypoxic tissues: Elimination of aspirin from 2-nitroimidazole derivatives
1999
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
2008
Colorectal cancer
2005
Role of gemcitabine in cancer therapy
2005
Microtubules as a target for anticancer drugs
2004 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC
2004
Integration of EGFR inhibitors with radiochemotherapy
2006
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
2006 Standout
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
2019
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
2006
Comèl-Netherton syndrome defined as primary immunodeficiency
2009
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies
2004
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
A crucial role for Lyn in TIMP‐1 erythroid cell survival signalling pathway
2013 StandoutNobel
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Head and Neck Cancer
2020 Standout
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
2008
Decision aids for people facing health treatment or screening decisions
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
2006
What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?
2008
Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy
2011
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
2016
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
2002
Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer
2017 Standout
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
2012
Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis
2006
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Works of Tim Maughan being referenced
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
2014
Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
2013
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
2012
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
2011
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
2000
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
2013
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study
2005
Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
2016
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
2002
Standardising RNA profiling based biomarker application in cancer—The need for robust control of technical variables
2017
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
2011
Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome
2005
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
2011
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
2007
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
2005
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
2007
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
2009
Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?
2004
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
2005
The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study
1991
Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.
2010
Exome Resequencing Identifies Potential Tumor-Suppressor Genes that Predispose to Colorectal Cancer
2013
Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience.
2011
Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial
2007
24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)
1997
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
2012
Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)
2004